Correlation of Antemortem Serum Creatine Kinase, Creatine Kinase-Mb, Troponin I, and Troponin T with Cardiac Pathology (Enzymes and Protein Markers) Correlation of Antemortem Serum Creatine Kinase, Creatine Kinase-Mb, Troponin I, and Troponin T with Cardiac Pathology (Enzymes and Protein Markers)

Correlation of Antemortem Serum Creatine Kinase, Creatine Kinase-Mb, Troponin I, and Troponin T with Cardiac Pathology (Enzymes and Protein Markers‪)‬

Clinical Chemistry 2000, March, 46, 3

    • CHF 3.00
    • CHF 3.00

Publisher Description

In recent years, serum troponins have been increasingly used in the diagnosis of acute coronary syndromes as studies have shown their greater clinical sensitivity over creatine kinase-MB (CK-MB) [4] (1, 2). In patients with non-Q-wave myocardial infarction (MI) or unstable angina, serum troponins can provide risk stratification for short-term (3-9) and long-term (9,10) cardiac events and mortality. This has been attributed mainly to the ability of serum troponins to detect microinfarcts, areas of necrosis too small to produce electrocardiographic changes or increased serum cardiac enzymes. Whereas increased short-term complications and mortality may understandably be explained by these microinfarcts, long-term events have also been attributed to complications of ischemia. Additionally, a high percentage of end-stage renal failure patients show increased cardiac troponin T (cTnT) in the absence of acute cardiac ischemia (11,12). There have been suggestions that these represent spurious increases arising from re-expression of the cardiac isoform, the fetal form, in skeletal muscles of these patients (13). We have observed a threefold increase in 1-year mortality in 172 hemodialysis patients with increased cTnT (14), and although increases in cTnT may result from silent MIs that occur frequently in these patients, the temporal pattern of increases was not in keeping with acute ischemic events. This raised the possibility that increased cTnT in this group of patients was indicative of chronic disease processes that compromise survival.

GENRE
Science & Nature
RELEASED
2000
1 March
LANGUAGE
EN
English
LENGTH
18
Pages
PUBLISHER
American Association for Clinical Chemistry, Inc.
SIZE
217.2
KB

More Books by Clinical Chemistry

The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments (Special Report) (Polymerase Chain Reaction) (Report) The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments (Special Report) (Polymerase Chain Reaction) (Report)
2009
D-Dimer Testing for Deep Venous Thrombosis: A Metaanalysis (Clinical Report) D-Dimer Testing for Deep Venous Thrombosis: A Metaanalysis (Clinical Report)
2004
Congenital Analbuminemia Attributable to Compound Heterozygosity for Novel Mutations in the Albumin Gene (Technical Briefs) Congenital Analbuminemia Attributable to Compound Heterozygosity for Novel Mutations in the Albumin Gene (Technical Briefs)
2005
Highly Sensitive Immunoprecipitation Method for Extracting and Concentrating Low-Abundance Proteins from Human Serum (Technical Briefs) Highly Sensitive Immunoprecipitation Method for Extracting and Concentrating Low-Abundance Proteins from Human Serum (Technical Briefs)
2005
Measurement of Pro-C-Type Natriuretic Peptide in Plasma (Technical Briefs) Measurement of Pro-C-Type Natriuretic Peptide in Plasma (Technical Briefs)
2005
Newborn Screening for Lysosomal Storage Disorders (Editorials) Newborn Screening for Lysosomal Storage Disorders (Editorials)
2005